Jonathan H Fox

Summary

Affiliation: University of Wyoming
Country: USA

Publications

  1. ncbi The mTOR kinase inhibitor Everolimus decreases S6 kinase phosphorylation but fails to reduce mutant huntingtin levels in brain and is not neuroprotective in the R6/2 mouse model of Huntington's disease
    Jonathan H Fox
    MassGeneral Institute for Neurodegenerative Disease and Harvard Medical School, Charlestown, MA, USA
    Mol Neurodegener 5:26. 2010
  2. ncbi Cysteine oxidation within N-terminal mutant huntingtin promotes oligomerization and delays clearance of soluble protein
    Jonathan H Fox
    Department of Veterinary Science and Neuroscience Graduate Program, University of Wyoming, Laramie, Wyoming 82070, USA
    J Biol Chem 286:18320-30. 2011

Detail Information

Publications2

  1. ncbi The mTOR kinase inhibitor Everolimus decreases S6 kinase phosphorylation but fails to reduce mutant huntingtin levels in brain and is not neuroprotective in the R6/2 mouse model of Huntington's disease
    Jonathan H Fox
    MassGeneral Institute for Neurodegenerative Disease and Harvard Medical School, Charlestown, MA, USA
    Mol Neurodegener 5:26. 2010
    ..In this study, we evaluated the mTOR kinase inhibitor and macroautophagy promoting drug everolimus in the R6/2 mouse model of HD...
  2. ncbi Cysteine oxidation within N-terminal mutant huntingtin promotes oligomerization and delays clearance of soluble protein
    Jonathan H Fox
    Department of Veterinary Science and Neuroscience Graduate Program, University of Wyoming, Laramie, Wyoming 82070, USA
    J Biol Chem 286:18320-30. 2011
    ..These findings show that inhibiting formation of oxidation-dependent huntingtin oligomers, or promoting their dissolution, may have protective effects in HD by decreasing the burden of soluble mutant huntingtin...